GlassScriptPhysician profile
Mario Garretto
NPI 1497701809
$5,926.65
in general payments reported to CMS, 2019-2025
31 companies · $1,015 in 2025
The $1,015 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,580 · 2020: $1,133 · 2021: $428 · 2022: $370 · 2023: $721 · 2024: $678 · 2025: $1,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,103 · Education: $311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,103.48 |
| Education | $311.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,622.79 | 2019-2025 | |
| Gilead Sciences, INC. | $1,076.30 | 2019-2025 | Livdelzi, Epclusa |
| Janssen Biotech, INC. | $914.95 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $323.20 | 2019-2024 | Entyvio |
| Pfizer INC. | $317.22 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $263.99 | 2019-2023 | Xifaxan, Plenvu |
| Braintree Laboratories, INC. | $183.22 | 2019-2021 | |
| Ucb, INC. | $148.81 | 2019-2020 | |
| Medical Device Business Services, INC. | $148.43 | 2019 | |
| Daiichi Sankyo INC. | $127.11 | 2019-2024 | Injectafer |
| Celgene Corporation | $122.46 | 2021-2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $110.63 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $85.09 | 2019 | |
| Aimmune Therapeutics, INC. | $56.56 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $55.69 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $40.47 | 2024-2025 | Hyrimoz |
| Ardelyx, INC. | $35.24 | 2024-2025 | Ibsrela |
| Celltrion USA INC. | $35.17 | 2024 | Zymfentra |
| Evoke Pharma, INC. | $34.85 | 2024-2025 | |
| Shionogi INC | $28.65 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $23.22 | 2023 | Terlivaz |
| Genzyme Corporation | $19.94 | 2024 | |
| Pharmacosmos Therapeutics INC. | $19.78 | 2025 | Monoferric |
| Intercept Pharmaceuticals, INC. | $19.58 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $19.34 | 2024 | Dupixent |
| Vivus LLC | $19.09 | 2020 | |
| Novo Nordisk INC | $17.46 | 2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $17.25 | 2019 | |
| Shire North American Group INC | $15.61 | 2019 | |
| Allergan, INC. | $12.53 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mario Garretto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.